https://www.selleckchem.com/pr....oducts/abraxane-nab-
Background A female survival advantage in cutaneous melanoma has been long recognized. However, whether this extends across all age groups, with risk stratification using the latest prognostic staging system or in the current era of efficacious systemic therapies is unknown. Therefore, we evaluated whether sex-based differences in melanoma survival persisted within a recent population-based patient cohort with consideration of these factors. Materials and Methods We identified stage II-IV cutaneous melanoma patients from
Like
Comment
Share
